Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

Sacha Gnjatic, Vincenzo Bronte, Laura Rosa Brunet, Marcus O. Butler, Mary L. Disis, Jérôme Galon, Leif G. Hakansson, Brent A. Hanks, Vaios Karanikas, Samir N. Khleif, John M. Kirkwood, Lance D. Miller, Dolores J. Schendel, Isabelle Tanneau, Jon M. Wigginton, Lisa H. Butterfield

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of cancer immunotherapy. Such interrogation of the tumor, blood, and host immune parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. To approach these opportunities for progress, the Society for Immunotherapy of Cancer (SITC) reconvened the Immune Biomarkers Task Force. Comprised of an international multidisciplinary panel of experts, Working Group 4 sought to make recommendations that focus on the complexity of the tumor microenvironment, with its diversity of immune genes, proteins, cells, and pathways naturally present at baseline and in circulation, and novel tools to aid in such broad analyses.

Original languageEnglish (US)
Article number44
JournalJournal for ImmunoTherapy of Cancer
Volume5
Issue number1
DOIs
StatePublished - May 16 2017

Fingerprint

Immunotherapy
Biomarkers
Neoplasms
Tumor Microenvironment
Advisory Committees
Immune System
Immunity
Therapeutics
Proteins

Keywords

  • Baseline immunity
  • Biomarkers
  • Cancer immunotherapy
  • Immune checkpoint inhibitors
  • Tumor microenvironment

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Gnjatic, S., Bronte, V., Brunet, L. R., Butler, M. O., Disis, M. L., Galon, J., ... Butterfield, L. H. (2017). Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. Journal for ImmunoTherapy of Cancer, 5(1), [44]. https://doi.org/10.1186/s40425-017-0243-4

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. / Gnjatic, Sacha; Bronte, Vincenzo; Brunet, Laura Rosa; Butler, Marcus O.; Disis, Mary L.; Galon, Jérôme; Hakansson, Leif G.; Hanks, Brent A.; Karanikas, Vaios; Khleif, Samir N.; Kirkwood, John M.; Miller, Lance D.; Schendel, Dolores J.; Tanneau, Isabelle; Wigginton, Jon M.; Butterfield, Lisa H.

In: Journal for ImmunoTherapy of Cancer, Vol. 5, No. 1, 44, 16.05.2017.

Research output: Contribution to journalReview article

Gnjatic, S, Bronte, V, Brunet, LR, Butler, MO, Disis, ML, Galon, J, Hakansson, LG, Hanks, BA, Karanikas, V, Khleif, SN, Kirkwood, JM, Miller, LD, Schendel, DJ, Tanneau, I, Wigginton, JM & Butterfield, LH 2017, 'Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy', Journal for ImmunoTherapy of Cancer, vol. 5, no. 1, 44. https://doi.org/10.1186/s40425-017-0243-4
Gnjatic, Sacha ; Bronte, Vincenzo ; Brunet, Laura Rosa ; Butler, Marcus O. ; Disis, Mary L. ; Galon, Jérôme ; Hakansson, Leif G. ; Hanks, Brent A. ; Karanikas, Vaios ; Khleif, Samir N. ; Kirkwood, John M. ; Miller, Lance D. ; Schendel, Dolores J. ; Tanneau, Isabelle ; Wigginton, Jon M. ; Butterfield, Lisa H. / Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. In: Journal for ImmunoTherapy of Cancer. 2017 ; Vol. 5, No. 1.
@article{03488bad15b5418a9c6716e1cd68472a,
title = "Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy",
abstract = "As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of cancer immunotherapy. Such interrogation of the tumor, blood, and host immune parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. To approach these opportunities for progress, the Society for Immunotherapy of Cancer (SITC) reconvened the Immune Biomarkers Task Force. Comprised of an international multidisciplinary panel of experts, Working Group 4 sought to make recommendations that focus on the complexity of the tumor microenvironment, with its diversity of immune genes, proteins, cells, and pathways naturally present at baseline and in circulation, and novel tools to aid in such broad analyses.",
keywords = "Baseline immunity, Biomarkers, Cancer immunotherapy, Immune checkpoint inhibitors, Tumor microenvironment",
author = "Sacha Gnjatic and Vincenzo Bronte and Brunet, {Laura Rosa} and Butler, {Marcus O.} and Disis, {Mary L.} and J{\'e}r{\^o}me Galon and Hakansson, {Leif G.} and Hanks, {Brent A.} and Vaios Karanikas and Khleif, {Samir N.} and Kirkwood, {John M.} and Miller, {Lance D.} and Schendel, {Dolores J.} and Isabelle Tanneau and Wigginton, {Jon M.} and Butterfield, {Lisa H.}",
year = "2017",
month = "5",
day = "16",
doi = "10.1186/s40425-017-0243-4",
language = "English (US)",
volume = "5",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

AU - Gnjatic, Sacha

AU - Bronte, Vincenzo

AU - Brunet, Laura Rosa

AU - Butler, Marcus O.

AU - Disis, Mary L.

AU - Galon, Jérôme

AU - Hakansson, Leif G.

AU - Hanks, Brent A.

AU - Karanikas, Vaios

AU - Khleif, Samir N.

AU - Kirkwood, John M.

AU - Miller, Lance D.

AU - Schendel, Dolores J.

AU - Tanneau, Isabelle

AU - Wigginton, Jon M.

AU - Butterfield, Lisa H.

PY - 2017/5/16

Y1 - 2017/5/16

N2 - As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of cancer immunotherapy. Such interrogation of the tumor, blood, and host immune parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. To approach these opportunities for progress, the Society for Immunotherapy of Cancer (SITC) reconvened the Immune Biomarkers Task Force. Comprised of an international multidisciplinary panel of experts, Working Group 4 sought to make recommendations that focus on the complexity of the tumor microenvironment, with its diversity of immune genes, proteins, cells, and pathways naturally present at baseline and in circulation, and novel tools to aid in such broad analyses.

AB - As cancer strikes, individuals vary not only in terms of factors that contribute to its occurrence and development, but as importantly, in their capacity to respond to treatment. While exciting new therapeutic options that mobilize the immune system against cancer have led to breakthroughs for a variety of malignancies, success is limited to a subset of patients. Pre-existing immunological features of both the host and the tumor may contribute to how patients will eventually fare with immunotherapy. A broad understanding of baseline immunity, both in the periphery and in the tumor microenvironment, is needed in order to fully realize the potential of cancer immunotherapy. Such interrogation of the tumor, blood, and host immune parameters prior to treatment is expected to identify biomarkers predictive of clinical outcome as well as to elucidate why some patients fail to respond to immunotherapy. To approach these opportunities for progress, the Society for Immunotherapy of Cancer (SITC) reconvened the Immune Biomarkers Task Force. Comprised of an international multidisciplinary panel of experts, Working Group 4 sought to make recommendations that focus on the complexity of the tumor microenvironment, with its diversity of immune genes, proteins, cells, and pathways naturally present at baseline and in circulation, and novel tools to aid in such broad analyses.

KW - Baseline immunity

KW - Biomarkers

KW - Cancer immunotherapy

KW - Immune checkpoint inhibitors

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85019239740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019239740&partnerID=8YFLogxK

U2 - 10.1186/s40425-017-0243-4

DO - 10.1186/s40425-017-0243-4

M3 - Review article

VL - 5

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 44

ER -